CDK2 and prostate cancer: In particular, glioblastoma, breast cancer, colon cancer, melanoma, lung adenocarcinoma, head and neck cancer, pancreatic cancer, liver cancer, and prostate cancer cohorts showed the most significantly (p < 0.001) elevated CDK2, CDK4, CDK6, and STAT3 expressions.